MMP9 and diabetes mellitus: The best predictors for 1-year adverse events included elevated levels of I-CAM > 239.7 ng/L and an MMP-9 level of over 1155 ng/mL, respectively, after adjustments for diabetes, hs-CRP, acute phase complications and LVEF for the overall study population.